Reishi

Ganoderma lucidum inhibits platelet aggregation through multiple mechanisms: reduction of thromboxane B2 synthesis, inhibition of ADP-induced platelet aggregation, and anticoagulant effects documented via prolonged INR, PT, and APTT in human studies. These pharmacodynamic effects are additive with warfarin and other anticoagulants, increasing bleeding risk. Clinical and experimental data confirm Reishi extracts prolong clotting times.

Monitor INR closely in patients on warfarin or other anticoagulants who use Reishi. Advise patients to report unusual bruising or bleeding. Consider dose adjustment of anticoagulant. Reishi should be discontinued at least 2 weeks prior to surgery due to antiplatelet effects. Inform surgeons and anesthesiologists of Reishi use.

Ganoderma lucidum polysaccharides and beta-glucans are potent immunomodulators that stimulate NK cell activity, T-cell proliferation, macrophage activation, and cytokine production (IFN-gamma, IL-2, TNF-alpha). This immunostimulatory profile directly opposes the immunosuppressive action of cyclosporine, tacrolimus, and mycophenolate used to prevent organ rejection and control autoimmune diseases. Additionally, triterpenoids from Reishi inhibit CYP3A4 in vitro, potentially elevating tacrolimus or cyclosporine plasma levels.

Reishi should be avoided in transplant recipients on immunosuppressive therapy. The dual risk of immune antagonism (rejection risk) and CYP3A4-mediated pharmacokinetic elevation of calcineurin inhibitors (tacrolimus, cyclosporine toxicity) is clinically significant. If a transplant patient uses Reishi, monitor drug levels, renal function, and signs of rejection or drug toxicity closely.

Ganoderma lucidum increases plasma antioxidant capacity through its polysaccharide and triterpenoid constituents. Many chemotherapy agents (doxorubicin, cisplatin, cyclophosphamide) rely on free radical generation and oxidative stress to kill cancer cells. Theoretically, Reishi antioxidants could reduce chemotherapy effectiveness by scavenging cytotoxic free radicals. Conversely, Reishi has demonstrated some antitumor synergy in combination with radiation in clinical trials. The net clinical effect is uncertain.

Patients undergoing chemotherapy should inform their oncologist about Reishi use before starting or continuing. Given the theoretical antagonism of free radical-dependent chemotherapy, Reishi should generally not be taken concurrently without oncologist approval. Timing-based separation (e.g., Reishi on non-chemo days) may be an option in specific cases under supervision.

Ganoderma lucidum has demonstrated antihypertensive effects in animal models and some human trials, mediated by inhibition of angiotensin-converting enzyme (ACE) activity by ganoderic acids, and by reducing vascular inflammation. When combined with antihypertensive medications, additive blood pressure lowering could result in symptomatic hypotension, particularly in elderly patients or those on multiple antihypertensives.

Blood pressure monitoring is recommended in patients on antihypertensive medication who initiate Reishi supplementation. Alert patients to symptoms of hypotension (dizziness, lightheadedness on standing). Antihypertensive dose adjustment may be needed. The interaction is generally mild but warrants attention in patients on multiple BP-lowering agents.

Ganoderma lucidum polysaccharides have demonstrated hypoglycemic effects in diabetic animal models and some human studies, mediated through enhanced insulin sensitivity, stimulation of glucose uptake, and inhibition of intestinal alpha-glucosidase. Combined use with antidiabetic medications (especially insulin or sulfonylureas) may cause additive blood glucose lowering and increase the risk of hypoglycemia.

Patients with diabetes taking Reishi should monitor blood glucose more closely, particularly when starting or changing the dose of Reishi. Be alert for hypoglycemia symptoms (tremor, sweating, confusion, palpitations). Inform the prescribing physician of Reishi use so antidiabetic medication doses can be adjusted if needed.

Lanostane triterpenoids from Ganoderma lucidum (particularly ganoderica F and ganodrol C) inhibit CYP1A2 in vitro, and Reishi polysaccharides inhibit CYP1A2 in animal models. CYP1A2 metabolizes several narrow therapeutic index drugs (theophylline, clozapine, olanzapine). CYP1A2 inhibition by Reishi constituents could reduce clearance of these drugs, elevating plasma concentrations and increasing risk of toxicity (theophylline: seizures/arrhythmias; clozapine: agranulocytosis, seizures).

Monitor theophylline plasma concentrations in patients taking Reishi, and reduce dose if levels rise. For clozapine, monitor for toxicity signs (excessive sedation, drooling, seizures) and check blood counts. Consider switching to antipsychotics with lower CYP1A2 dependence if Reishi is medically necessary. Clinical significance of this CYP1A2 interaction requires confirmation in human pharmacokinetic studies.

Reishi (Ganoderma lucidum) contains ganoderic acids and lanostane triterpenoids documented to inhibit platelet aggregation in both in vitro and clinical studies. Co-administration with NSAIDs (which inhibit thromboxane A2 synthesis via COX-1 inhibition) or antiplatelet drugs (clopidogrel, ticagrelor, which inhibit P2Y12 ADP receptor) creates additive antiplatelet effects, significantly increasing bleeding risk beyond that of either agent alone.

Monitor for signs of increased bleeding (bruising, prolonged bleeding from cuts, GI bleeding, haematuria) in patients using reishi alongside NSAIDs or antiplatelet drugs. Consider temporarily discontinuing reishi 1-2 weeks before planned surgical procedures or other invasive interventions. Assess bleeding risk before combining with dual antiplatelet therapy.

Ganoderic acid A (GAA), the primary bioactive triterpenoid in reishi, inhibits CYP3A4 non-competitively (IC50 15.05 µM, Ki 7.16 µM) and CYP2D6 competitively (IC50 21.83 µM, Ki 10.07 µM) in human liver microsomes. CYP3A4-metabolized statins (simvastatin, lovastatin, atorvastatin) may reach elevated plasma levels, increasing risk of myopathy and rhabdomyolysis. Tamoxifens conversion to its active metabolite endoxifen requires CYP2D6; inhibition by reishi may reduce tamoxifen efficacy in ER-positive breast cancer patients.

Use reishi with caution in patients on CYP3A4-metabolized statins; consider switching to renally-cleared statins (pravastatin, rosuvastatin) that are less CYP3A4-dependent. For patients on tamoxifen for breast cancer treatment, close oncology monitoring of disease response is warranted if reishi is used concurrently. Monitor CK levels if myopathy symptoms arise in statin users.

Reishi polysaccharides (β-1,3 and β-1,6 glucans) and triterpenoids are potent immunostimulatory agents that activate macrophages, enhance NK cell cytotoxicity, and upregulate pro-inflammatory cytokines (IL-1, IL-6, TNF-α) via Toll-like receptor signaling. Co-administration with corticosteroids, which suppress immune function by reducing cytokine synthesis and lymphocyte activity, creates a direct pharmacodynamic antagonism. Reishis immune activation may reduce the anti-inflammatory or immunosuppressive efficacy of corticosteroids, particularly in autoimmune conditions.

Advise patients with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) or those on corticosteroid therapy to avoid reishi supplementation. The immunostimulatory actions of reishi directly oppose the therapeutic goals of corticosteroid treatment in these settings. This concern extends to patients on steroid-containing regimens for organ transplant maintenance.